# US 12,213,966 B2 · Methods of reducing plasma level of macrophage migratory inhibitory factor in patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,213,966 B2
- Document ID: US12213966B2
- Status: Granted
- Kind: B2
- Application number: 17/222,673
- Filed: 2021-04-05
- Published: 2021-10-07
- Granted: 2025-02-04
- Earliest claimed: 2020-04-06
- Assignees: MediciNova, Inc.
- Applicants: MediciNova, Inc.
- Inventors: Yuichi Iwaki; Kazuko Matsuda
- Web page: https://patentgrep.com/patent/US12213966B2

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a method of reducing plasma level of macrophage migratory inhibitory factor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

## Claims

### Claim 1

A method of reducing plasma level of macrophage migratory inhibitory factor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutically acceptable salt thereof, wherein the subject is diagnosed with or suffering from severe viral-induced pneumonia.

### Claim 2 (depends on 1)

The method of claim 1, wherein ibudilast, or the pharmaceutically acceptable salt thereof, is administered orally.

### Claim 3 (depends on 1)

The method of claim 1, wherein ibudilast, or the pharmaceutically acceptable salt thereof, is administered intravenously.

### Claim 4 (depends on 1)

The method of claim 1, wherein ibudilast, or the pharmaceutically acceptable salt thereof, is administered for at least 1 day.

### Claim 5 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of ibudilast, or the pharmaceutically acceptable salt thereof, is from 0.1 mg to 720 mg per day.

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is administered as a single dose or is divided into two, three, or four doses.

### Claim 7 (depends on 1)

The method of claim 1, wherein the severe viral-induced pneumonia is associated with an infection by an influenza virus, a respiratory syncytial virus, a coronavirus, a rhinovirus, an adenovirus, or a parainfluenza virus.

### Claim 8 (depends on 7)

The method of claim 7, wherein the infection by a coronavirus is COVID-19.

### Claim 9 (depends on 1)

The method of claim 1, wherein a reduction of the plasma level of macrophage migratory inhibitory factor in the subject is observed within 12 hours after a first dose of ibudilast is administered.

### Claim 10 (depends on 1)

The method of claim 1, wherein a reduction of the plasma level of macrophage migratory inhibitory factor in the subject is observed within 12 hours after administration of ibudilast for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.

### Claim 11 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of ibudilast, or the pharmaceutically acceptable salt thereof, is about 100 mg per day.